1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.
Funding Opportunity Number: RFA-DA-25-060. Assistance Listing: 93.279. Funding Instrument: G. Category: ED,HL. Award Amount: Up to $1.5M per award.
Get alerted about grants like this
Get emailed when new opportunities from “National Institutes of Health” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Public housing authorities / Indian housing authorities; Native American tribal organizations (other than Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses; Others (see text field entitled Additional Information on Eligibility for clarification). Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Confirm the full requirements in the official notice before applying.
The current listing shows up to $1.5M per award. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) are due March 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
This opportunity targets applicants in Alaska and Hawaii. Check the official notice for exact location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
NIH R25 Summer Research Education Experience Program is a grant from the National Institutes of Health (NIH) that funds universities and institutions of higher education to provide summer research experiences in environmental health sciences to high school students, college undergraduates, and science teachers. Administered through the National Institute of Environmental Health Sciences (NIEHS), the program aims to attract young people to scientific careers and help teachers communicate about the scientific process more effectively. Eligible applicants are U.S. institutions eligible for NIH grants. The application deadline was March 17, 2026.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
As of October 1, 2025, NIH no longer posts Notices of Funding Opportunity in the NIH Guide — Grants.gov is now the single official source (NOT-OD-25-143). The weekly Guide table-of-contents email that thousands of investigators relied on to discover funding no longer lists opportunities. Combined with the January 25, 2026 SciENcv certified-PDF requirement, the mechanics of finding and applying for NIH money have changed underneath everyone. Here is how to rebuild your discovery workflow so nothing slips through.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleThe NIH Director's New Innovator Award (DP2, RFA-RM-27-002) closes August 17, 2026, offering roughly 30 Early Stage Investigators up to $475,000 in direct costs a year for five years — $2.375 million total — to pursue bold ideas without the preliminary data a standard R01 demands. Here is how the High-Risk, High-Reward program actually evaluates applications, who qualifies, and why the usual R01 instincts will sink you.
Read article